Web of Science: 8 cites, Scopus: 8 cites, Google Scholar: cites,
Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injection
Ascher-Svanum, Haya (Eli Lilly and Company, Indianapolis)
Novick, Diego (Universitat Autònoma de Barcelona. Departament de Psiquiatria i de Medicina Legal)
Haro Abad, Josep Maria (Universitat de Barcelona. Parc Sanitari Sant Joan de Déu)
Bertsch, Jordan (Universitat de Barcelona. Parc Sanitari Sant Joan de Déu)
McDonnell, David (Eli Lilly and Company, Indianapolis)
Detke, Holland (Eli Lilly and Company, Indianapolis)

Data: 2014
Resum: Little is known about the long-term changes in the functioning of schizophrenia patients receiving maintenance therapy with olanzapine long-acting injection (LAI), and whether observed changes differ from those seen with oral olanzapine. This study describes changes in the levels of functioning among outpatients with schizophrenia treated with olanzapine-LAI compared with oral olanzapine over 2 years. This was a secondary analysis of data from a multicenter, randomized, open-label, 2-year study comparing the long-term treatment effectiveness of monthly olanzapine-LAI (405 mg/4 weeks; n=264) with daily oral olanzapine (10 mg/day; n=260). Levels of functioning were assessed with the Heinrichs-Carpenter Quality of Life Scale. Functional status was also classified as "good", "moderate", or "poor", using a previous data-driven approach. Changes in functional levels were assessed with McNemar's test and comparisons between olanzapine-LAI and oral olanzapine employed the Student's t -test. Over the 2-year study, the patients treated with olanzapine-LAI improved their level of functioning (per Quality of Life total score) from 64. 0-70. 8 (P <0. 001). Patients on oral olanzapine also increased their level of functioning from 62. 1-70. 1 (P <0. 001). At baseline, 19. 2% of the olanzapine-LAI-treated patients had a "good" level of functioning, which increased to 27. 5% (P <0. 05). The figures for oral olanzapine were 14. 2% and 24. 5%, respectively (P <0. 001). Results did not significantly differ between olanzapine-LAI and oral olanzapine. In this 2-year, open-label, randomized study of olanzapine-LAI, outpatients with schizophrenia maintained or improved their favorable baseline level of functioning over time. Results did not significantly differ between olanzapine-LAI and oral olanzapine.
Drets: Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. Creative Commons
Llengua: Anglès
Document: Article ; recerca ; Versió publicada
Matèria: Antipsychotics ; Functioning ; Olanzapine long-acting injection ; Quality of life ; Schizophrenia
Publicat a: Neuropsychiatric Disease and Treatment, Vol. 10 (june 2014) , p. 1125-1131, ISSN 1178-2021

DOI: 10.2147/NDT.S61409
PMID: 25018631


7 p, 211.7 KB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats

 Registre creat el 2018-01-29, darrera modificació el 2021-08-08



   Favorit i Compartir